Poseida Therapeutics Inc.

05/09/2024 | Press release | Distributed by Public on 05/09/2024 13:32

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR T P BCMA ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.